Vascular inflammation in moderate‐to‐severe atopic dermatitis is associated with enhanced Th2 response

Villani, Axel-Patrice; Pavel, Ana B.; Wu, Jianni; Fernandes, Marie; Maari, Catherine; Proulx, Étienne Saint‐Cyr; Jack, Carolyn; Glickman, Jacob W.; Choi, Soo In; He, Helen; Ungar, Benjamin; Estrada, Yeriel; Kameyama, Naoya; Zhang, Ning; Gonzales, Juana; Tardif, Jean‐Claude; Krueger, James G.; Bissonnette, Robert; Guttman‐Yassky, Emma

doi:10.1111/all.14859

Cited by 33 publications

(20 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AD, particularly severe disease, has been shown to be associated with an increased incidence of hypertension, angina pectoris and peripheral arterial disease [ 149 , 150 , 153 ], which may increase MACE occurrence. Moderate-to-severe AD, particularly severe disease, was also linked to vascular inflammation and to subclinical atherosclerosis [ 154 ]. Paradoxically, lipid levels, traditional risk factors for CVD, are reduced in patients with AD [ 155 ].…”

Section: Adverse Events Of Special Interest: Baricitinib Clinical Evi...mentioning

confidence: 99%

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

Bieber

Feist²,

Irvine

et al. 2022

Adv Ther

View full text Add to dashboard Cite

Baricitinib is an oral, selective inhibitor of Janus kinase (JAK)1/JAK2 that transiently and reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a number of chronic inflammatory diseases; accordingly, baricitinib has been studied and approved for the treatment of several rheumatological and dermatological disorders, as well as COVID-19. This narrative review summarises and discusses the safety profile of baricitinib across these diseases, with special focus on adverse events of special interest (AESI) for JAK inhibitors, using integrated safety data sets of clinical trial data, and puts findings into context with the underlying risk in the respective disease populations, using supporting literature. We show that rates of infection with baricitinib generally reflected the inherent risk of the disease populations being treated, with serious infections and herpes zoster being more frequent in rheumatic diseases than in dermatological disorders, and herpes simplex being reported particularly in atopic dermatitis. Similarly, rates of major adverse cardiovascular events (MACE), venous thromboembolism (VTE) and malignancies were generally within or below the ranges reported for the respective disease populations, thereby reflecting the underlying risk; these events were therefore more frequent in patients with rheumatic diseases than in those with dermatological disorders, the latter of whom generally had low absolute risk. AESI were usually more common in patients with risk factors specific for each event. When a population similar to that of ORAL Surveillance was considered, the incidence rate of MACE with baricitinib was numerically lower than that reported with tofacitinib and similar to that of tumour necrosis factor inhibitors. No safety concerns were observed in hospitalised patients with COVID-19 who received baricitinib for up to 14 days. Identifying the patterns and likelihoods of AEs that occur during treatment in large groups of patients with different diseases can help the physician and patient better contextualise the benefit-to-risk ratio for the individual patient.

show abstract

Section: Adverse Events Of Special Interest: Baricitinib Clinical Evi...mentioning

confidence: 99%

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

Bieber

Feist²,

Irvine

et al. 2022

Adv Ther

View full text Add to dashboard Cite

show abstract

“…This observation indicates that it may have some potential pathogenesis relationships between these two diseases. In practice, vascular inflammation in AD is linked to Th2 response and clinical severity that has been suggested previously 40 . Among the six critical genes, three up-regulated genes (S100A7, S100A9, SERPINB4) are involved in multiple immune processes, while one down-regulated gene (BTC) plays a prominent role in positive regulation of epidermal growth.…”

Section: Discussionmentioning

confidence: 75%

Accurate diagnosis of atopic dermatitis by applying random forest and neural networks with transcriptomic data

Zhou

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. But the great heterogeneity of AD makes it difficult to design an accurate diagnostic pipeline based on traditional diagnostic methods. In other words, the AD diagnosis has suffered from an inaccurate bottleneck. Thus, it is necessary to develop a novel and accurate diagnostic model to supplement existing methods. The recent development of advanced gene sequencing technologies enables potential in accurate AD diagnosis. Inspired by this, we developed an accurate AD diagnosis based on transcriptomic data in skin tissue. Using these data of 149 subjects, including AD patients and healthy controls, from Gene Expression Omnibus (GEO) database, we screened differentially expressed genes (DEGs) of AD and identified six critical genes (PPP4R1, SERPINB4, S100A7, S100A9, BTC, and GALNT6) by random forest classifier. In a follow-up study of these genes, we constructed a neural network model (average AUC=0.943) to automatically distinguish subjects with AD from healthy controls. Among these critical genes, we found that PPP4R1 and GALNT6 had never been reported to be associated with AD. Although further replications in other cohorts are needed, our findings suggest that these genes may be developed into useful biomarkers of AD diagnosis and may provide invaluable clues or perspectives for further researches on the pathogenesis of AD.

show abstract

“…Vascular inflammation and markers of atherosclerosis were shown to correlate with markers of Th2 inflammation in the skin and blood of patients with AD, and AD patients have increased levels of proteins associated with cardiovascular risk. 140,141 Epidemiologic evidence is mounting for small associations between AD and hypertension, peripheral and coronary artery disease, congestive heart failure, and acute events such as myocardial infarction and cardiovascular death (Supplementary Tables XV to XXI; available via Mendeley at https:// data.mendeley.com/datasets/cm9h5g2m63/1).…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults

Davis

Drucker

Alikhan

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Vascular inflammation in moderate‐to‐severe atopic dermatitis is associated with enhanced Th2 response

Cited by 33 publications

References 99 publications

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

Accurate diagnosis of atopic dermatitis by applying random forest and neural networks with transcriptomic data

American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults

Contact Info

Product

Resources

About